Patrys (ASX:PABDA) Construction In Progress: A$0.00 Mil (As of Dec. 2025)


What is Patrys Construction In Progress?

Patrys ASX:PABDA -4.88% Construction In Progress is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Patrys Construction In Progress Historical Data

* Premium members only.

The historical data trend for Patrys's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Patrys Construction In Progress Chart

Patrys Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Patrys Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Patrys Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of A$0.00 Mil mean?
Patrys (ASX:PABDA) has a Construction In Progress of A$0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Patrys and its competitors.
Is Patrys' Construction In Progress too high?
Patrys' current Construction In Progress is A$0.00 Mil.
How does Patrys' Construction In Progress compare to VRTX and REGN?
Patrys' Construction In Progress of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Patrys and its competitors. Patrys's current Construction In Progress is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Patrys stock overvalued right now?
Patrys (ASX:PABDA) has a current Construction In Progress of A$0.00 Mil. The current Construction In Progress is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Patrys (ASX:PABDA), the current Construction In Progress is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Patrys Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.